The hair regeneration of cells from RFP mice when injected into GFP mice.

<p>(a) Abundant hair follicles were reconstructed when dermal and epidermal cells were injected together, but no hair follicles were reconstructed when epidermal cells (b) or dermal cells (c) were injected alone. (d) Fourteen days after the injection of dermal and epidermal cells: HE sections, arrows indicate the regenerated HFs (green) and the panniculus carnosus (black). (e, f) Frozen sections of reconstructed hair follicles observed under a fluorescence microscope, red indicates donor cells, green indicates host cells. (g) DAPI staining of reconstructed hair follicle. (h) Synthesis, arrows indicate the green fluorescent cells (white). Scale bars = 1 mm in a, b, and c; 100 μm in d, e, f, g, and h.</p

Hair reconstruction of the cell spheroids inside the capsules 10 d after the transplantation.

<p>(a) Cell spheres inside the capsules were acquired for single transplantation into nude mice. Thirty days after transplantation, mature hair follicles were reconstructed successfully. (b) Red fluorescence of the reconstructed hair follicle. (c) Green fluorescence figure of the reconstructed hair follicle. (d) DAPI staining of the reconstructed hair follicle. (e) Synthesis, arrows indicate GFP cells from host mice (red). Scale bars = 50 μm in a; and 100 μm in b, c, d, and e.</p

The cultivation of capsules <i>in vitro</i>.

<p>Dermal and epidermal cells were encapsulated in capsules (a). Cells in the capsules gradually aggregated into small multicellular aggregates (b). Dermal cells (red) and epidermal cells (green) were observed under an inverted fluorescence microscope (c, d). Four days later, multicellular aggregates merged into hybrid spheroids (e). Seven days later, the morphology of hybrid spheroids became stable (f, g [10 d after encapsulation]). Twenty days after capsules were cultured <i>in vitro</i>, cell spheroids were taken out of capsules (h). HE sections of cell spheres were made; neither hair follicles nor concentric circles were observed (i). Cell spheroids attached to the wall when reseeded in culture dishes; cells inside then migrated from the spheroids (j–l, 0 d, 2 d, and 7 d after reseeding, respectively). The capsules were cultured <i>in vitro</i> for 30 d, no apparent change was observed (m). Confocal micrographs taken at 7d (n–p). These images showed dermal (green) and epidermal cells (red) in cell spheroids. The z reconstituted image clearly showed that dermal cells were located in the center and epidermal cells were sorted to the surface (q). Scale bars = 1 mm in a, b, c, d, e, f, g, h, j, l, and m; 200 μm in k; 100 μm in i, n, o, p, and q.</p

Additional file 1: of Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population

This file contains Tables S1–S7, including Table S1. CBF ratios in European, American, and Eastern Asian cohorts; Table S2. NPM1 mutation ratios in European and our cohorts; Table S3. FLT3-ITD mutation ratios in European and our cohorts; Table S4. FLT3-ITD mutation ratios in older patients from Chinese cohort against European and American cohorts; Table S5. CBF leukemia ratios in older patients from Japanese and Chinese cohorts against European and American cohorts; Table S6. NPM1 mutation ratios in older patients from Chinese cohort against European and American cohorts; and Table S7. Outcomes in European, American, and Eastern Asian cohorts. (PDF 568 kb

The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia

<div><p>Hematopoietic recovery is considered to be associated with the number of multipotent hematopoietic stem cells in the bone marrow, as observed in functional assays involving stem cell transplantation. However, there is little evidence related to hematopoietic recovery in non-transplantation settings, which is accomplished by endogenous hematopoietic cells. A recent study suggested that progenitors are the main contributors during this steady-state hematopoiesis, which differs from exogenous transplantation. We hypothesized that endogenous progenitor support post-chemotherapy hematopoietic recovery. To investigate the potential impact of these progenitor cell percentage on hematopoietic recovery, we retrospectively analyzed the percentage of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells (P cells) and hematopoietic recovery in 223 newly diagnosed acute myeloid leukemia patients during two courses of consolidation chemotherapy after complete remission. We found that a lower P cell percentage was significantly associated with prolonged neutropenia recovery time after the first and second courses of consolidation chemotherapy (p = 0.001; p = 0.045, respectively). We also observed similar results with regard to platelet recovery time after the first course of consolidation chemotherapy (p = 0.000). Univariate analysis showed that P cell percentage and consolidation chemotherapy regimens, and not gender, age, induction chemotherapy regimens, infection grade, WHO classification and NCCN risk category, were associated with neutrophil recovery after chemotherapy. Multivariate analysis demonstrated that P cell percentage is an independent factor affecting neutrophil recovery capacity for both the first and second courses (p = 0.008; p = 0.032, respectively). Our results indicate that CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells before each course of chemotherapy is independently associated with chemotherapy-related hematopoietic reconstitution capacity. These findings may help modify future chemotherapy regimens based on progenitor cell percentages.</p></div

Additional file 1: Figure S1. of An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification

The 3-year OS of 97 previously diagnosed de novo adult AEL patients according to age group. The 3-year OS of <40, 40–60 and >60 age group. (TIFF 170 kb

Additional file 3: of An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification

Raw data. The clinical characteristic of 97 previously diagnosed de novo adult acute erythroid leukemia patients. The clinical characteristic of 97 previously diagnosed de novo adult acute erythroid leukemia patients were listed, including MDS/AML subtype, MRC cytogenetic risk, survival data, gene mutation and so on. (DOC 239 kb

Additional file 2: Table S1. of An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification

The ratio of different cytogenetic risk category in different age group. The ratio of different cytogenetic risk category (intermediate and unfavorable risk) in <40, 40–60, >60 age group. (DOCX 12 kb

Multivariate analysis for ANC recovery in consolidation one.

<p>Multivariate analysis for ANC recovery in consolidation one.</p

Chemotherapy-impaired hematopoietic recovery ability.

<p>Differences in bone marrow recovery capacity represented as time of neutropenia (A) and platelet recovery time (B) after the first and second course of chemotherapy.</p